MGNX - MacroGenics, Inc.
| Previous Close | 15.07 |
| Open | 15.23 |
| Bid | 0.00 x 900 |
| Ask | 16.94 x 800 |
| Day's Range | 15.06 - 15.32 |
| 52 Week Range | 9.87 - 32.32 |
| Volume | 148,367 |
| Avg. Volume | 658,456 |
| Market Cap | 742.203M |
| Beta (3Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.47 |
| Earnings Date | Nov 5, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.09 |
- GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics’ management will participate in one-on-one meetings and a panel discussion titled “Targeted Oncology - A Break in the Clouds” in New York City on Monday, August 12, 2019. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview in New York City on August 13, 2019, at 1:55 p.m. ET. A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.
- Thomson Reuters StreetEvents
Edited Transcript of MGNX earnings conference call or presentation 31-Jul-19 8:30pm GMT
Q2 2019 MacroGenics Inc Earnings Call
- Zacks
MacroGenics (MGNX) Reports Q2 Loss, Misses Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of 32.29% and -39.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
MacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results
ROCKVILLE, Md., July 31, 2019 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.
- GlobeNewswire
MacroGenics Announces Date of Second Quarter 2019 Financial Results Conference Call
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2019 after the market closes on Wednesday, July 31, 2019. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Wednesday, July 31, 2019 at 4:30 p.m. ET. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm.
- Simply Wall St.
An Intrinsic Calculation For MacroGenics, Inc. (NASDAQ:MGNX) Suggests It's 31% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of MacroGenics, Inc...
- GlobeNewswire
MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it plans to advance the development of flotetuzumab, its investigational bispecific CD123 x CD3 DART® molecule, in patients with primary refractory acute myeloid leukemia (AML), a difficult-to-treat patient population. To date, MacroGenics has enrolled 50 patients at the recommended Phase 2 dose (RP2D) in the Phase 1 monotherapy study, including 30 patients with primary refractory AML. The updated clinical data from this study will be submitted for presentation at the 2019 American Society for Hematology (ASH) Annual Meeting.
- Benzinga
The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 10) CONMED Corporation (NASDAQ: CNMD ) Eidos Therapeutics ...
- GlobeNewswire
MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, and I-Mab Biopharma (I-Mab), a China and U.S.-based clinical-stage biopharmaceutical company committed to the discovery and development of first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, announced today that the companies have entered into an exclusive collaboration and license agreement to develop and commercialize enoblituzumab. This investigational drug is an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates MacroGenics’ proprietary Fc Optimization technology platform.
- Zacks
Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab
Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.
- TheStreet.com
2 Small Biotechs With Sagging Shares but Promising Prospects
As discussed in my column on Monday, small biotechs that need to raise money over the next 12 months as they ramp up sales on recently approved products have been particularly hit hard. Developmental concerns with no approved products are doing much better provided they have adequate cash runways. Data support what should be a successful New Drug Application (NDA) in the near future, but the information wasn't as overwhelming positive as some investors evidently hoped for as MacroGenics shares saw some profit taking in the days after the event.
- Zacks
Implied Volatility Surging for MacroGenics (MGNX) Stock Options
Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.
- GlobeNewswire
MacroGenics to Participate in Jefferies Healthcare Conference
Rockville, MD, May 30, 2019 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.
- GlobeNewswire
MacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a conference call and audio webcast on Tuesday, June 4 at 1:30 p.m. CT (2:30 p.m. ET). MacroGenics management will be joined by external guest presenters to review the margetuximab Phase 3 SOPHIA study presentation at the American Society of Clinical Oncology (ASCO) annual meeting and discuss ongoing and future clinical development plans for margetuximab, an Fc-optimized anti-HER2 antibody. To participate in the MacroGenics ASCO 2019 Conference Call, please dial (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and provide the Conference ID: 9959793.
- Motley Fool
3 Cancer Treatment Stocks to Buy Right Now
These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.
- Simply Wall St.
Is MacroGenics, Inc.'s (NASDAQ:MGNX) CEO Overpaid Relative To Its Peers?
In 2001 Scott Koenig was appointed CEO of MacroGenics, Inc. (NASDAQ:MGNX). This report will, first, examine the CEO...
- Investor's Business Daily
Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting
Biotech companies Iovance Biotherapeutics, MacroGenics and Mirati Therapeutics were among the winners in a slew of data for cancer treatments released late Wednesday. Stocks rose Thursday.
- Motley Fool
Why MacroGenics, Inc. Stock Is Heating Up Today
MacroGenics shares jumped in response to another major clinical update today.
- Benzinga
The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 15) Applied Therapeutics Inc (NASDAQ: APLT ) (debuted on ...
- Insider Monkey
Microsoft, Amazon, and More: Why These Stocks Are Trending
It's getting close to 13F filing season and several stocks such as Amazon and JPMorgan are in the spotlight because of it. Furthermore, Microsoft is also in the spotlight due to an unrelated issue concerning some of its software. Without further ado, let's analyze why traders are watching each stock and how the smart money […]
- GlobeNewswire
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced additional details of the results from the Phase 3 SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies. Margetuximab is an investigational, immune-enhancing monoclonal antibody derived from the Company’s proprietary Fc Optimization technology platform.
- Motley Fool
3 Stocks With Big News Coming at ASCO 2019
These cancer drug developers could report market-moving news soon.
- Thomson Reuters StreetEvents
Edited Transcript of MGNX earnings conference call or presentation 26-Feb-19 9:30pm GMT
Q4 2018 MacroGenics Inc Earnings Call
Motley FoolMacrogenics Inc (MGNX) Q1 2019 Earnings Call Transcript
MGNX earnings call for the period ending March 31, 2019.
- Zacks
MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
MacroGenics (MGNX) delivered earnings and revenue surprises of -4.21% and -15.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
